Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
clinical trials
fda
life sciences
national blog main
patisiran
3
×
rna interference
hereditary transthyretin amyloidosis
national top stories
onpattro
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
biotech
boehringer ingelheim
craig mello
deals
dicerna pharamceuticals
drugs
givosiran
hepatitis b
hepatitis b virus
inotersen
john maraganore
new york blog main
new york top stories
nobel prize
paul matteis
pfizer
roche
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
What
drug
pharmaceuticals
3
×
alnylam
fda
medicine
rnai
afternoon
ago
alnylam’s
approval
approved
caught
causing
dicerna
disease
eye
gene
gets
hepatitis
history
indicated
intended
interference
landmark
making
medicines
nod
ok
onpattro
patisiran
pay
pharma
producing
protein
quick
research
rna
roche
second
seek
Language
unset
Current search:
pharmaceuticals
×
patisiran
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
